Analyst Expectations for Marinus Pharma's Future

Over the past 3 months, 5 analysts have published their opinion on Marinus Pharma MRNS stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 2 0 0 0
Last 30D 1 0 0 0 0
1M Ago 1 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 1 2 0 0 0

According to 5 analyst offering 12-month price targets in the last 3 months, Marinus Pharma has an average price target of $25.6 with a high of $28.00 and a low of $21.00.

Below is a summary of how these 5 analysts rated Marinus Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 1.54% from the previous average price target of $26.00.

Stay up to date on Marinus Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!